Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Rare Tumour × Gemcitabine × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Pancreatic Neoplasms 268 Carcinoma, Non-Small-Cell Lung 143 Lung Neoplasms 81 Breast Neoplasms 78 Urinary Bladder Neoplasms 72 Cholangiocarcinoma 52 Neoplasms 46 Neoplasm Metastasis 45 Ovarian Neoplasms 38 Biliary Tract Neoplasms 38 Lymphoma, Large B-Cell, Diffuse 29 Lymphoma 28 Hodgkin Disease 27 Sarcoma 26 Nasopharyngeal Carcinoma 24 Recurrence 23 Gallbladder Neoplasms 23 Carcinoma, Transitional Cell 23 Adenocarcinoma 22 Adenocarcinoma of Lung 20 Triple Negative Breast Neoplasms 18 Fallopian Tube Neoplasms 18 Bile Duct Neoplasms 18 Carcinoma, Renal Cell 15 Lymphoma, Non-Hodgkin 14 Carcinoma, Ovarian Epithelial 14 Urethral Neoplasms 13 Kidney Neoplasms 13 Colorectal Neoplasms 13 Leiomyosarcoma 12

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡